Oruka Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDOruka Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings contraction of 16% provides fundamental context to the price action. However, price is extended 35% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $69.49 | +30.39% | ABOVE |
| 50 SMA | $66.87 | +35.48% | ABOVE |
| 100 SMA | $53.94 | +67.96% | ABOVE |
| 150 SMA | $46.23 | +95.96% | ABOVE |
| 200 SMA | $40.45 | +124.00% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ORKA in an uptrend right now?
ORKA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ORKA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ORKA overbought or oversold?
ORKA's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is ORKA outperforming the market?
ORKA has a Relative Strength (RS) Rating of 97 out of 99. Yes, ORKA is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is ORKA in its 52-week range?
ORKA is trading at $90.60, which is 99% of its 52-week high ($91.12) and 99% above its 52-week low ($10.97).
How volatile is ORKA?
ORKA has a Beta of 1.46 and 52-week volatility of 77%. It's more volatile than the S&P 500 - expect bigger swings.